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Chemotherapy of advanced breast cancer: outcome and prognostic factors
W.M. Gregory, P. Smith, M.A. Richards, C.J. Twelves, R.K. Knight & R.D. Rubens
Imperial Cancer Research Fund, Clinical Oncology Unit, Guy's Hospital, London SE] 9RT, UK.
Summary The outcome for 758 consecutive patients who had received one or more chemotherapy regimens
for recurrent or metastatic breast cancer is presented. The response rate following first line treatment was
34%. Median duration of response was 7.8 months, median time to progression was 3.7 months and median
survival was 7.9 months. The only factor predicting for response, of factors recorded at presentation and at
initiation of chemotherapy, was the use of anthracycline based regimens, though this may reflect the patient
selection policy. Initial disease free interval, presence of liver metastases and use of anthracyclines were
significantly related to time to progression. Several factors related to survival following first chemotherapy, but
anthracycline usage showed only a very weak correlation.
One third of patients (249/758) received two or more chemotherapy regimens. The response rate (16%) and
median time to progression (2.3 months) were significantly worse than for first line treatment. The outcome
after third line chemotherapy was very similar to that observed following second line treatment. Achievement
of an objective response with first line chemotherapy predicted for second response, but with insufficient power
to be of use in selecting patients for subsequent chemotherapy. Time to progression following first line
chemotherapy did not influence that after second line treatment.
Chemotherapy for advanced breast cancer is palliative, not
curative, in intent. A variety of cytotoxic agents are active
and often used in combination, with objective response rates
from 40% to 60% frequently being reported, with median
durations of6 to 12 months (Rubens et al., 1978; Muss et al.,
1978; Steiner et al., 1983; Tormey et al., 1984; Perry et al.,
1987; Coates et al., 1987; Italian Multicentre Breast Study
with Epirubicin, 1988; Namer et al., 1990; Carmo-Pereira et
al., 1991; Richards et al., 1992). Whilst a response is likely to
be associated with a reduction in symptoms, this is to a
variable extent counter-balanced by toxic effects of treatment.
It would, therefore be of value to be able to predict which
patients are likely to respond, and to spare patients with little
or no chance of benefit from the rigours of treatment. This
applies both to the selection of patients for first line
chemotherapy and to the selection of patients suitable for
second or third line chemotherapy after progression follow-
ing earlier treatment. Unfortunately, reliable predictive tests
are not currently available.
The aim of this study was to evaluate the parameters
which may influence response to chemotherapy including
characteristics of the tumour at presentation, the number and
sites of metastatic disease, the treatment regimen employed
and the efficacy of earlier chemotherapy treatments. We have
reviewed data from all the patients at the Guy's Breast Unit
who received at least one chemotherapy regimen for
advanced breast cancer over the 16 year period to 1991. We
sought to identify factors of value in predicting response to
chemotherapy which may be of use in selecting appropriate
treatment for individual patients.
Patients and methods
Between 1975 and 1991 a total of 1756 patients with
inoperable locally recurrent or metastatic breast cancer were
managed at the Guy's Hospital Breast Unit. In general, the
policy adopted within the Unit has been to manage asym-
ptomatic disease expectantly. Systemic therapy is given to
patients with symptomatic progressive disease, and some-
times as prophylaxis against anticipated complications, which
cannot be controlled by local measures (i.e. surgery or
radiotherapy). Chemotherapy is usually reserved for the
treatment of disease whcih can no longer be controlled by
endocrine treatment, except in cases of rapidly progressive
disease when a response to endocrine treatment is considered
unlikely.
This report concerns the outcome from the time of start of
chemotherapy for the 758 patients who have received at least
one chemotherapy regimen. A variety of chemotherapy
regimens were used, often in clinical trials, the results of
which have previously been reported. These have included
doxorubicin (60-75 mg m-2 given 3 weekly) either alone or
with vincristine (Rubens et al., 1978; Steiner et al., 1983;
Richards et al., 1992), doxorubicin 25 mg m-2 given weekly
(Richards et al., 1992), doxorubicin combined with mito-
mycin C (Amiel et al., 1984), epirubicin (90-120mgm2)
given 3 weekly (Carmo-Pereira et al., 1991), epirubicin
25 mg m-2 weekly in patients with abnormal liver biochemis-
try (Twelves et al., 1989; Twelves et al., 1991), mitozantrone
12 mg m-2 3 weekly (Coleman et al., 1984), various combina-
tions of cyclophosphamide, methotrexate and 5-fluorouracil
(CMF) (Engelsman et al., 1991), and mitomycin C with
vinblastine (MMC and Vinb) (Radford et al., 1985).
Response was assessed by UICC criteria (Hayward et al.,
1978). All patients who died within 6 weeks of starting
chemotherapy were included with those having progressive
disease. Response durations and time to progression were
measured from the date of starting chemotherapy. The rela-
tionship between response to first line chemotherapy and
tumour characteristics at initial presentaiton, previous
systemic treatment (e.g. adjuvant therapy and endocrine
treatment for advanced disease), initial relapse free interval
and time from first relapse to start of chemotherapy were
studied. For patients with operable disease at presentation,
initial relapse free interval was calculated from the date of
first histological diagnosis to first recurrence. For patients
who presented with locally advanced disease the equivalent
interval was taken to be from first diagnosis to first evidence
of tumour progression. Patients with metastatic disease at
first presentation were considered to have no initial relapse
free interval. The relationship between response and sites of
disease at the time of chemotherapy and the type of
chemotherapy given were also investigated. Pretreatment
evaluation normally included full clinical examination, full
blood count, liver biochemistry, chest radiograph and isotope
bone scan with radiographs of areas of abnormal uptake.
Imaging of the liver was not routinely undertaken unless
there was clinical hepatomegaly or abnormal liver biochemis-
try. Unfortunately, performance status was not routinely
recorded for these patients, and could not therefore be
included in the analysis.
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Statistical methods
Survival (S) and relapse free survival (RFS) were calculated
by the method of Kaplan and Meier (Kaplan & Meier, 1958),
with significance being determined using the log-rank test
(Peto et al., 1977), and multivariate analysis being under-
taken with Cox's proportional hazards model (Cox, 1972).
Survival data were analysed using the SUREAL package.
Response rates were compared using Fisher's Exact Test.
Multivariate logistic regression was used to determine
independent predictors of response, using the BMDP com-
puter package.
Results
Four hundred and ten of the 1756 patients with recurrent or
metastatic breast cancer were alive at the time of analysis. Of
the 1346 patients who have died, 15% received no systemic
therapy for their recurrent or metastatic disease, 33%
received endocrine therapy only, 11% received chemotherapy
only and 41% received both endocrine therapy and
chemotherapy. This study focuses on the 758 patients who
received chemotherapy at some time following relapse (for
those with operable disease), progression (for those with
locally advanced disease) or at any time for those who
presented with metastatic disease.
The characteristics at the time of initial diagnosis of the
758 patients (677 dead, 81 currently alive) who received
chemotherapy for advanced breast cancer are shown in Table
I. Fifteen per cent of the patients with operable disease had
Table I Characteristics atprimarydiagnosis with breast cancerfor758
patients who received chemotherapy
Mean
Age (years)
Tumour size (cm)
Stage
Histology
Nodal status
(of operable
patients only)
ER status
PR status
Primary treatment
Adjuvant treatment
(operable
patients)
51
4.4
Range
(19-81)
(0-20)
Operable node negative
Operable node positive
Operable node unknown
Locally advanced
Metastatic
Unknown
Ductal grade I
Ductal grade II
Ductal grade III
Lobular
Other
Unknown/ungraded
Negative
1 -3 nodes + ve
4-9 nodes + ve
>9 nodes + ve
+ ve but number unknown
Unknown
Positive
Negative
Unknown
Positive
Negative
Unknown
Mastectomyc
Tumourectomy + radiotherapyc
Primary radiotherapyb
Primary endocrine therapy
Primary chemotherapy
None
Endocrine therapy
Chemotherapy
147
334
85
137
54
1
9
195
213
39
19
283
147
149
88
80
17
85
294
149
315
194
219
345
424
142
132
31
29
433
61
72
19
44
11
18
7
0
26
28
5
3
37
26
26
16
14
3
15
39
20
42
26
29
46
56
19
17
4
4
77
11
13
received adjuvant chemotherapy and 11% had received
adjuvant endocrine therapy (ovarian ablation or tamoxifen).
Ninety five of 136 (70%) patients with locally advanced
disease had received chemotherapy, endocrine therapy or
both as part of their initial treatment. The median relapse
free interval for those who initially had operable disease was
21 months and the median time to first progression for those
with locally advanced disease was 11 months. A total of 515
(68%) patients had received endocrine treatment following
relapse before starting chemotherapy. The median time from
first distant relapse to starting chemotherapy was 7 months.
Sites of disease at the start of chemotherapy for recurrent
or metastatic disease are shown in Table II. The treatment
regimens used are shown in Table III. Doxorubicin and
epirubicin given alone (n = 350) or in combination with other
agents (n = 52) were the most commonly used first line
treatments (402/758 = 53%). The combination of cyclophos-
phamide, methotrexate and fluorouracil (CMF) was in
general used as first line chemotherapy when anthracyclines
were not considered appropriate, or as second line chemo-
therapy. The combination of mitomycin C and vinblastine
was generally used as a second line or later treatment.
Outcomefollowingfirst line chemotherapy
Survival after first line chemotherapy is shown in Figure 1.
Response to first line chemotherapy was assessable in 639 of
these 758 patients (84%). The objective response rate (com-
plete and partial responses) was 34%, with 31% having
stable disease (SD) and 36% having progressive disease (PD)
or dying within 6 weeks of starting treatment. Median time
to progression was 4 months. Thirty two per cent of the 758
patients treated had a period of more than 6 months before
disease progression, and 9% had progression times longer
than 1 year. Among responders the median time to progres-
sion was 7.8 months, compared with 5.2 months for those
with stable disease (P<0.001). Median survival for all
Table II Distribution of disease at start of first line chemotherapy
(n = 758)
1. Extent ofdisease (758 patients)
Locoregional only
Locoregional + distant metastases
Distant metastases only
2. Number ofsites ofdistant disease (718 patients)
3. Sites ofdistant disease (1697 sites)
Soft tissue (breast, lymphatic, cutaneous)
Bone
Visceral (e.g. lung/pleura but not liver)
Liver
Otherb
40
466
252
1 143
2 186
3 166
>, 4 223
354
453
355
271
264
5
61
33
20
26
23
31
%a
49
63
49
38
37
aThese percentages are out of the 718 patients with distant disease.
bIncluding brain, meningeal, pericardial, abdominal (not liver), ascites,
brachial plexus.
Table III Treatment regimens used at successive treatments
Treatment number
Treatment regimen 1 2 3 4 5 Total
Doxorubicin or epirubicin 402 74 22 5 0 503
alone or in combination
CMF 265 84 5 1 0 355
MMC + Vinb 18 64 21 4 0 107
Mitoxantrone 50 11 8 0 0 69
Othersa 23 16 2 0 1 42
Total 758 249 58 10 1 1076
a4-deoxydoxorubicin (13), prednimustine (21), oral cyclophos-
phamide (6), didox (2).
a > 10 fmol mg- cytosol protein. bIncludes locally advanced breast
cancer patients treated with radiotherapy ± hormone therapy and/or
chemotherapy. clncludes patients whose stage is not known because
their surgery was performed at another hospital.990 W.M. GREGORY et al.
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Figure 1 Survival from the start of first line chemotherapy (n = 758).
patients from the start of chemotherapy was 7.9 months. For
responders median survival was 13.3 months, compared with
10.6 months for those with stable disease and 2.5 months for
those with progressive disease.
Multivariate analysis of factors predicting for first response
is shown in Table IV. A separate regression was performed
for non-responders to predict for stable as opposed to pro-
gressive disease. The response rate for those who received
doxorubicin or epirubicin regimens was 40% (137/346) com-
pared with 29% (64/219) for those receiving CMF and 20%
(15/74) for those receiving other chemotherapy regimens.
This finding was independent of other recorded factors, as
demonstrated by the multivariate results (Table IV). How-
ever, it may still result from the patient selection policy, since
these were not randomised studies. The response rate for
patients with liver metastases was 32%, which was similar to
that for other sites. However, a lower proportion (22%) of
patients with liver metastases had stable disease (Table IV)
and the median survival from start of chemotherapy for
patients with liver metastases (4.5 months) was significantly
shorter than that for patients without liver metastases (9.8
months; P<0.0001). Although nodal status showed a
significant correlation with response, since some 18 possible
prognostic factors were considered, and the P-value was only
0.05, this result should be treated with caution.
Table IV Logistic regression results for prediction of response to
first-line chemotherapy
Factor'
Liver metastases
Ductal grade III at presentation
Anthracycline regimensc
Positive nodal status
Any v
none'
NS
NS
0.000
0.05
Response category
's Non-responders only:
b SD vs PD
< 0.0001
0.004
4 0.006
NS
aThe following factors were included in the regressions, but were not
found to be significant (P>0.05): age at diagnosis, age at start of
first-linechemotherapy, stage, previous endocrinetherapy foradvanced
disease, sites ofmetastases at chemotherapy other than liver (Table II),
local vs distant disease at start of chemotherapy, number of sites of
distantmetastases, chemotherapy regimens otherthanthosewhichwere
anthracyclinebased, andprevious adjuvantendocrine orchemotherapy
(CMF). bi.e. CR + PR vs SD + PD. 'This factor correlates with better
prognosis. The remaining factors correlate with worse prognosis.
N = 758
6 7 8 9
Factors which were related to time to progression on
univariate and multivariate analysis are shown in Table V.
The only significant factors were initial disease free interval,
presence of liver metastases and use of anthracyclines. The
mean age at treatment was 55 years (range 24-84) but this
did not predict for time to progression. Time to progression
was considerably shorter in patients with liver metastases
(Figure 2). Time to progression was, however, the same for
patients with local disease, distant disease or both (Figure 3).
A number of factors were related to survival following
first-line chemotherapy (Table VI). Again, the significance of
the different treatment regimens should be viewed with cau-
tion, both because of the barely significant P-values, and
because of the non-randomised nature of the studies. Other-
wise factors were the same as those which predicted time to
progression, but with a number of additions. In particular,
histological grade, and to a lesser extent age, both appeared
to have prognostic significance. Survival was also better for
those having local as opposed to distant disease at the time
of treatment.
The survival and time to progression of patients presenting
initially with locally advanced disease was similar to that of
the group as a whole. Furthermore, excluding this group
from the analysis made only very minor differences to the
results, and the analyses presented therefore include these
patients.
Second and successive chemotherapy regimens
A total of 249 patients received two or more chemotherapy
regimens. These patients comprised 92/216 (43%) who had
achieved an objective response to first line chemotherapy, 71
of 195 (36%) with stable disease, 69 of 228 (30%) with
progressive disease and 17 of 119 (14%) of those whose first
response had not been assessable.
Response to second line treatment was assessable in 186 of
the 249 (75%) patients (Table VII). The objective response
rate was 16%, with 33% having SD and 51% having PD.
The response rate following second line chemotherapy was
approximately half that for first line treatment, this difference
being statistically significant (P<0.0001). A separate series
of logistic regressions was used to see if any factors predicted
for second or subsequent response; the same factors were
considered as for the first response, with the addition of
treatment number itself as a variable. No predictive factorsCHEMOTHERAPY OF ADVANCED BREAST CANCER 991
Table V Factors predicting for worse time to progression after first-line
chemotherapy
Univariate Multivariate
Factor' X2 P x2 P
Liver metastases 21.9 <0.001 27.8 <0.001
Initial disease free interval <2 years 14.5 <0.001 18.3 <0.001
Anthracyclines vs other drugsb 8.3 0.004 12.3 <0.001
aThe following factors were included in the regressions, but were not found to be
significant (P>0.05): age at diagnosis, age at start offirst-line chemotherapy, stage,
ductal grade, nodal status, previous endocrine therapy for advanced disease, sites of
metastases at chemotherapy other than liver (Table II), local vs distant disease at start
ofchemotherapy, numberofsites ofdistant metastases, chemotherapy regimens other
than those which were anthracycline based, and previous adjuvant endocrine or
chemotherapy (CMF). 'This factor correlates with better prognosis. The remaining
factors correlate with worse prognosis.
X2= 22.8
P < 0.001
Not involved N = 487
1 2 3 4 5
Time (years)
Figure 2 Time to progression following first line chemotherapy according to presence of liver metastases.
X2= 0.62
P = 0.73
Distant N = 252
Both N = 466
2 3
Time (years)
Figure 3 Time to progression following first line chemotherapy according to distribution of disease (locoregional vs metastatic).
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Table VI Factors predicting for worse survival after first-line chemotherapy
Factor'
Liver metastases
Initial disease free interval <2 years
Distant as opposed to local disease at CT
Miscellaneous metastatic sites'
Increasing histological gradec
Increasing age at diagnosis
Visceral metastases (excluding liver)
MMC + Vinblastine vs other drugs
Anthracyclines vs other drugs'
Univariate
x2 p
41.3 <0.0001
16.2 <0.0001
25.8 <0.0001
10.1 0.001
20.2 <0.0001
4.1 0.04
2.8 0.09
5.0 0.02
1.5 0.22
Multivariate
x2 p
42.5 <0.0001
19.8 <0.0001
13.6 0.0002
13.3 0.0003
12.2 0.0005
5.1 0.02
4.7 0.03
4.0 0.05
4.0 0.05
'ThefactorsincludedintheregressionswereasforTableV.Thosenotlistedabovewere
not found to be significant (P<0.05). bSee Table II for a list ofthese sites. cNon-ductal
histologies similar to ductal grade 2.
Table VII Response rates for successive chemotherapy regimens in assessable
patients
Response
CT Regimen CR + PR (%) SD (%) PD (%) ALL
First 216 (34) 195 (31) 228 (36) 639
Second 30 (16) 61 (33) 95 (51) 186
Third 9 (18) 16 (33) 24 (49) 49
All 255 (29) 272 (31) 347 (40) 874
were found in this analysis. However, in 181 patients where
response to both first line and second line treatment was
assessed (Table VIII) response to prior chemotherapy did
influence the likelihood of response to second line
chemotherapy. Seventeen of 70 (24%) patients who achieved
complete response (CR) or partial response (PR) with first
line chemotherapy responded to second line treatment, com-
pared with 13 of 111 (12%) who had not achieved an objec-
tive response with first line treatment (P = 0.04).
Median time to progression (TTP) following second line
chemotherapy was 2.5 months with only 15% of patients
having TTP longer than 6 months and only 5% having TTP
longer than 12 months (Figure 4). Median TTP for res-
ponders to second line chemotherapy (6.5 months) was
longer than that for patients with SD (3.7 months;
P<0.001). However, time to progression following second
line treatment did not appear to be related to response to
first line chemotherapy (Figure 5) or to first TTP. Those with
first TTP longer than the median had similar second TTP to
those with shorter TTP following first chemotherapy (Figure
6).
Response was assessable in 49 of 58 (84%) patients who
received third line chemotherapy. Response rates and time to
progression for those who received such treatment were
similar to those observed for second line treatment (Table
VII and Figure 4). Of the 23 assessable patients receiving
third line chemotherapy having shown no previous response
with 1st or 2nd line treatment five (22%) showed an objective
response.
Discussion
The primary aim of systemic treatment for patients with
metastatic breast cancer is to control the disease and thereby
Table VIII Relationship between responses to first and second
chemotherapy regimens
Response to Response tofirst chemotherapy
second chemotherapy CR/PR SD PD Total
CR/PR 17 6 7 30
SD 21 20 18 59
PD 32 29 31 92
70 (39%) 55 (30%) 56 (31%) 181
to relieve symptoms and improve quality of life. The impact
of chemotherapy on survival has never been directly assessed
in this group of patients because of the difficulties inherent in
conducting randomised trials with a 'no chemotherapy' arm.
While it is likely that some patients survive longer as a result
ofreceiving chemotherapy, the survival benefit attributable to
chemotherapy remains uncertain. It is therefore essential that
the potential benefits of systemic therapy should be carefully
weighed against the likely toxicities. Achievement of objective
response is associated with improvement in symptoms, and
performance status (Baum et al., 1980). Identification of
patients who are likely to respond to chemotherapy therefore
remains an important goal.
Most reports of outcome following chemotherapy for
metastatic breast cancer are concerned with patients entered
into clinical trials with strict eligibility criteria. In contrast to
this we have examined the outcome for all patients who
received chemotherapy at a single institution. Only 53% of
the patients who have died with metastatic breast cancer had
received chemotherapy for advanced disease, whereas most
(74%) had received endocrine therapy. This reflects the
policy adopted in this unit, which has generally been to give
endocrine therapy ahead of chemotherapy, except in patients
with a pattern of metastatic disease which is considered to be
imminently life threatening.
The response rate (34%) to first line chemotherapy in this
unselected series was, not surprisingly, lower than that fre-
quently reported for patients entered into phase III trials,
including those conducted in this unit (Rubens et al., 1978;
Steiner et al., 1983; Amiel et al., 1984; Richards et al., 1992).
For example, the response to anthracyclines (40%) is lower
than that reported in several randomised trials (Rubens et al.,
1978; Steiner et al., 1983; Amiel et al., 1984; Perry et al.,
1987; Italian Multicentre Breast Study with Epirubicin, 1988;
Namer et al., 1990; Perez et al., 1991; Richards et al., 1992),
probably because patients with liver metastases and markedly
abnormal liver biochemistry have been included in this study
(Twelves et al., 1989; Twelves et al., 1991).
The higher response rates observed with anthracyclines
compared to other combinations in this study may in part
reflect patient selection, although the observation is consis-
tent with the high activity and probable survival benefits seen
with doxorubicin and epirubicin in this disease (A'Hern et
al., 1993). The other factors which were found to be related
to first response, TTP and survival following first-line
chemotherapy for advanced disease are similar to thoseCHEMOTHERAPY OF ADVANCED BREAST CANCER 993
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Figure 4 Time to progression according to treatment number (1, 2, 3 and 4 only).
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Figure 5 Time to progression following second line treatment according to response to first line treatment (n = 249).
identified in three other large studies of patients with metas-
tatic breast cancer (Swenerton et al., 1979; Namer et al.,
1990; Falkson et al., 1991). In all four studies initial disease
free interval and liver metastases (or, in the Swenerton et al.
study, abnormal liver function tests) were identified as impor-
tant prognostic factors. However, neither systemic adjuvant
therapy nor number of sites of disease were identified as
having prognostic importance in this study, in contrast to the
other three studies. This may result from the smaller number
of patients in this study, and it may also be that the specific
sites of disease identified here are more important than the
total number of sites. Performance status was also found to
have considerable prognostic significance in two of the other
three studies (Swenerton et al., 1979; Namer et al., 1990), but
this factor was not routinely recorded in this study. With this
prognostic information it is possible to identify groups of
patients with high and low probabilities of response (Falkson
et al., 1991). However, it remains impossible to exclude a
reasonable possibility of worthwhile response in individual
patients. Although administration of previous adjuvant CMF
was not found to be predictive for subsequent TTP after
chemotherapy, the P-value (0.07) was of borderline signi-
ficance. This result is not therefore in conflict with the results
of a recent publication from this centre in which there was a
small but significant (P = 0.03) decrease in TTP for patients
who had received previous adjuvant CMF (Houston et al.,
1993).
Histological grade was the main factor from initial presen-
21994 W.M. GREGORY et al.
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Figure 6 Time to progression following second line treatment according to time to progression after first line treatment.
tation with breast cancer which predicted for survival after
chemotherapy; this may be because this factor relates to the
tumour's growth rate, and thus carries prognostic significance
throughout the tumour's history.
We have confirmed that response rates and TTP following
second line chemotherapy are lower than those for first line
treatment. Methods for selecting patients who are likely to
benefit from second line or subsequent chemotherapies have
previously received little attention. Approximately one third
of our patients who had received first line chemotherapy
went on to receive further chemotherapy. This group
included substantial numbers of patients who had exper-
ienced objective response, stable disease and progressive
disease following first line therapy. As might have been
expected, those who had previously responded had a higher
response rate with second line therapy. However, this effect
was relatively small. Perhaps surprisingly, time to progression
after first line chemotherapy was not an indicator of TTP
following second line therapy. Thus, although the probability
of a second response can be estimated, it remains impossible
to predict which individual patients are likely to derive
benefit from such treatment.
In conclusion, although 30%-40% of patients will res-
pond to chemotherapy, it is difficult to identify such patients
on the basis of currently available prognostic factors. For
second-line and later chemotherapies the response rate is
smaller, with some 15%-20% achieving an objective res-
ponse, but still no useful predictive factors to identify this
group. It would seem therefore, that a clinically based judge-
ment for each individual is still the only way of deciding
whether or not to give chemotherapy for advanced breast
cancer, and that it will be necessary to go on treating patients
with the expectation that many of them will receive no
benefit from the treatment. For the patient, deciding whether
to have a particular treatment or not can be a difficult and
highly subjective decision (Slevin et al., 1990). These results
may enable clinicians to provide patients with better inform-
ation on which to make this decision in advanced breast
cancer.
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